Trials / Completed
CompletedNCT01910038
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose until 0.1 mg/Kg/d or less after 6 months of treatment. In this study, we hypothesized that adding 3 months of tocilizumab to prednisone could increase the percentage from 40 to 70%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | corticoids+ tocilizumab 8mg/Kg/4 weeks |
Timeline
- Start date
- 2013-11-08
- Primary completion
- 2015-12-01
- Completion
- 2016-06-13
- First posted
- 2013-07-29
- Last updated
- 2017-11-30
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01910038. Inclusion in this directory is not an endorsement.